An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs RXI 109 (Primary)
- Indications Hypertrophic scars
- Focus Therapeutic Use
- Sponsors Phio Pharmaceuticals
- 21 Feb 2018 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
- 18 Dec 2017 Results presented in an RXi Pharmaceuticals media release.
- 18 Dec 2017 According to an RXi Pharmaceuticals media release, Joseph P. Hunstad is the principal investigator for the Company's Dermatology Clinical Program with RXI-109.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History